Eli Lilly to Acquire Psychedelic Drugmaker AtaiBeckley for $2.8 Billion
Eli Lilly (LLY) agreed to acquire clinical-stage biotech company AtaiBeckley, a developer of psychedelic-based mental health treatments, in an all-cash deal valued at approximately $2.8 billion upfront with potential additional payments up to $1 billion based on regulatory and development milestones. The acquisition is expected to close by Q3 2026.
Topics: mental_health_treatment pharmaceuticals psychedelic_drugs